Human cytomegalovirus immediate-early 1 protein (IE1)

The human cytomegalovirus immediate-early 1 protein (IE1) is a major nuclear phosphoprotein produced immediately after viral entry into a cell and is crucial for initiating viral replication and reactivation from latency[3][5]. IE1 is a multifunctional regulator, acting as a potent viral and cellular transcriptional modulator and as a major antagonist of host intrinsic defenses—most notably by binding to and disassembling promyelocytic leukemia (PML) protein nuclear bodies, counteracting intrinsic cellular immunity[1][7]. It interacts directly with host nucleosomes via specific domains and can downregulate MHC class I molecules, contributing to viral immune evasion[2][3]. IE1 is intensely targeted by both CD8 and CD4 T-cell responses, making it an important antigen for immunodiagnostic and potential immunotherapeutic strategies in HCMV infection[4]. There are currently no approved drugs that specifically inhibit IE1. IE1 is not a receptor or enzyme, but a uniquely viral chromatin-binding and immunomodulatory protein within the β-herpesvirus family[7]. Its detection is critical for laboratory diagnosis of active cytomegalovirus replication, particularly in immunocompromised hosts[6]. The protein’s high sequence and structural conservation among cytomegaloviruses is linked to its pivotal role in viral replication and immune evasion[3][7].

Other names

Immediate-early 1 antigenMajor immediate-early protein 1hCMV IE1CMV IE1IE-1

Not applicable for approved therapeutics specifically targeting IE1; in research and immunotherapeutic contexts, immune modulation through IE1-specific T cells or antibodies is being explored[4].